165 related articles for article (PubMed ID: 24980692)
1. Why dried blood spots are an ideal tool for CYP1A2 phenotyping.
De Kesel PM; Lambert WE; Stove CP
Clin Pharmacokinet; 2014 Aug; 53(8):763-71. PubMed ID: 24980692
[TBL] [Abstract][Full Text] [Related]
2. Paraxanthine/Caffeine Concentration Ratios in Hair: An Alternative for Plasma-Based Phenotyping of Cytochrome P450 1A2?
De Kesel PM; Lambert WE; Stove CP
Clin Pharmacokinet; 2015 Jul; 54(7):771-81. PubMed ID: 25603821
[TBL] [Abstract][Full Text] [Related]
3. CYP1A2 phenotyping in dried blood spots and microvolumes of whole blood and plasma.
De Kesel PM; Lambert WE; Stove CP
Bioanalysis; 2014; 6(22):3011-24. PubMed ID: 25096793
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.
Bosilkovska M; Samer C; Déglon J; Thomas A; Walder B; Desmeules J; Daali Y
Basic Clin Pharmacol Toxicol; 2016 Sep; 119(3):284-90. PubMed ID: 27009433
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations.
Fuhr U; Rost KL; Engelhardt R; Sachs M; Liermann D; Belloc C; Beaune P; Janezic S; Grant D; Meyer UA; Staib AH
Pharmacogenetics; 1996 Apr; 6(2):159-76. PubMed ID: 9156694
[TBL] [Abstract][Full Text] [Related]
6. Does volumetric absorptive microsampling eliminate the hematocrit bias for caffeine and paraxanthine in dried blood samples? A comparative study.
De Kesel PM; Lambert WE; Stove CP
Anal Chim Acta; 2015 Jun; 881():65-73. PubMed ID: 26041521
[TBL] [Abstract][Full Text] [Related]
7. Potassium-based algorithm allows correction for the hematocrit bias in quantitative analysis of caffeine and its major metabolite in dried blood spots.
De Kesel PM; Capiau S; Stove VV; Lambert WE; Stove CP
Anal Bioanal Chem; 2014 Oct; 406(26):6749-55. PubMed ID: 25168119
[TBL] [Abstract][Full Text] [Related]
8. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva.
Fuhr U; Rost KL
Pharmacogenetics; 1994 Jun; 4(3):109-16. PubMed ID: 7920690
[TBL] [Abstract][Full Text] [Related]
9. Validation of a high-performance liquid chromatography assay for quantification of caffeine and paraxanthine in human serum in the context of CYP1A2 phenotyping.
Koch JP; ten Tusscher GW; Koppe JG; Guchelaar HJ
Biomed Chromatogr; 1999 Jun; 13(4):309-14. PubMed ID: 10416066
[TBL] [Abstract][Full Text] [Related]
10. The basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots.
Donzelli M; Derungs A; Serratore MG; Noppen C; Nezic L; Krähenbühl S; Haschke M
Clin Pharmacokinet; 2014 Mar; 53(3):271-282. PubMed ID: 24218006
[TBL] [Abstract][Full Text] [Related]
11. Variability of cytochrome P450 1A2 activity over time in young and elderly healthy volunteers.
Simon T; Becquemont L; Hamon B; Nouyrigat E; Chodjania Y; Poirier JM; Funck-Brentano C; Jaillon P
Br J Clin Pharmacol; 2001 Nov; 52(5):601-4. PubMed ID: 11736870
[TBL] [Abstract][Full Text] [Related]
12. Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma.
Perera V; Gross AS; McLachlan AJ
Biomed Chromatogr; 2010 Oct; 24(10):1136-44. PubMed ID: 20853468
[TBL] [Abstract][Full Text] [Related]
13. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.
Parra-Guillen ZP; Berger PB; Haschke M; Donzelli M; Winogradova D; Pfister B; Früh M; Gillessen S; Krähenbühl S; Kloft C; Joerger M
Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):309-315. PubMed ID: 28444958
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Capitainer-B Microfluidic Device as a New Hematocrit-Independent Alternative for Dried Blood Spot Collection.
Velghe S; Stove CP
Anal Chem; 2018 Nov; 90(21):12893-12899. PubMed ID: 30256092
[TBL] [Abstract][Full Text] [Related]
15. Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans.
Rasmussen BB; Brøsen K
Br J Clin Pharmacol; 1997 Mar; 43(3):253-8. PubMed ID: 9088579
[TBL] [Abstract][Full Text] [Related]
16. Analysis of caffeine and paraxanthine in human saliva with ultra-high-performance liquid chromatography for CYP1A2 phenotyping.
Jordan NY; Mimpen JY; van den Bogaard WJ; Flesch FM; van de Meent MH; Torano JS
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Jul; 995-996():70-3. PubMed ID: 26038236
[TBL] [Abstract][Full Text] [Related]
17. Assessment of CYP1A2 activity in clinical practice: why, how, and when?
Faber MS; Jetter A; Fuhr U
Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):125-34. PubMed ID: 16128905
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics.
Perera V; Gross AS; Xu H; McLachlan AJ
J Pharm Pharmacol; 2011 Sep; 63(9):1161-8. PubMed ID: 21827488
[TBL] [Abstract][Full Text] [Related]
19. Paraxanthine/caffeine ratio: as an index for CYP1A2 activity in polycyclic aromatic hydrocarbons exposed subjects.
Wittayalertpanya S; Hinsui Y; Lawanprasert S
J Med Assoc Thai; 2003 Jun; 86 Suppl 2():S310-7. PubMed ID: 12930004
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of a reversed-phase HPLC method for CYP1A2 phenotyping by use of a caffeine metabolite ratio in saliva.
Begas E; Kouvaras E; Tsakalof AK; Bounitsi M; Asprodini EK
Biomed Chromatogr; 2015 Nov; 29(11):1657-63. PubMed ID: 25891161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
